Vancomycin HCl | CAS#1404-93-9 | CAS#123409-00-7 | Antibiotic

Vancomycin HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558307

CAS#: 1404-93-9 (HCl)

Description: Vancomycin is an antibiotic used to treat a number of bacterial infections. Vancomycin acts by inhibiting proper cell wall synthesis in gram-positive bacteria. Due to the different mechanism by which gram-negative bacteria produce their cell walls and the various factors related to entering the outer membrane of gram-negative organisms, vancomycin is not active against gram-negative bacteria (except some nongonococcal species of Neisseria). The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Under normal circumstances, this is a five-point interaction.

Chemical Structure

Vancomycin HCl

CAS# 1404-93-9 (HCl)

Instruction

Theoretical Analysis

MedKoo Cat#: 558307
Name: Vancomycin HCl
CAS#: 1404-93-9 (HCl)
Chemical Formula: C66H76Cl3N9O24
Exact Mass: 0.00
Molecular Weight: 1,485.723
Elemental Analysis: C, 53.36; H, 5.16; Cl, 7.16; N, 8.48; O, 25.84

Price and Availability

Size	Price	Availability
1g	USD 250	2 Weeks
2g	USD 450	2 Weeks
5g	USD 750	2 Weeks
10g	USD 1050	2 Weeks
25g	USD 1650	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 1404-93-9 (HCl) 123409-00-7 (HCl hydrate) 1404-90-6 (free base),

Synonym: Vancomycin HCl; Vanco-saar; Vancocin; Vancocin HCl; Vancocine.

IUPAC/Chemical Name: (1S,2R,18R,19R,22S,25R,28R,40S)- 48- {[(2S,3R,4S,5S,6R)- 3- {[(2S,4S,5S,6S)- 4- amino- 5- hydroxy- 4,6- dimethyloxan- 2- yl]oxy}- 4,5- dihydroxy- 6- (hydroxymethyl)oxan- 2- yl]oxy}- 22- (carbamoylmethyl)- 5,15- dichloro- 2,18,32,35,37- pentahydroxy- 19- [(2R)- 4- methyl- 2- (methylamino)pentanamido]- 20,23,26,42,44- pentaoxo- 7,13- dioxa- 21,24,27,41,43- pentaazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta- 3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49- pentadecaene- 40- carboxylic acid hydrochloride

InChi Key: LCTORFDMHNKUSG-XTTLPDOESA-N

InChi Code: InChI=1S/C66H75Cl2N9O24.ClH/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92;/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95);1H/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-;/m0./s1

SMILES Code: C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O.Cl

Appearance: White to off-white solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in water

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#1404-93-9 (Vancomycin HCl salt) CAS#123409-00-7 (Vancomycin HCl hydrate); CAS#1404-90-6 (Vancomycin free base).

Certificate of Analysis:

View CoA: current batch, Lot# C21B09B09

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,485.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Bhongsatiern JJ, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin CM. Renal function descriptors in neonates: Which creatinine-based formula best describes vancomycin clearance? J Clin Pharmacol. 2015 Sep 28. doi: 10.1002/jcph.650. [Epub ahead of print] Review. PubMed PMID: 26412385.

2: Javorska L, Krcmova LK, Solichova D, Solich P, Kaska M. Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography - A review. J Sep Sci. 2015 Sep 9. doi: 10.1002/jssc.201500600. [Epub ahead of print] Review. PubMed PMID: 26351070.

3: O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015 Jul 24;8:217-30. doi: 10.2147/IDR.S54125. eCollection 2015. Review. PubMed PMID: 26244026; PubMed Central PMCID: PMC4521680.

4: Hanrahan T, Whitehouse T, Lipman J, Roberts JA. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents. 2015 Sep;46(3):249-53. doi: 10.1016/j.ijantimicag.2015.04.013. Epub 2015 Jun 7. Review. PubMed PMID: 26141230.

5: Spagnolo AM, Orlando P, Panatto D, Amicizia D, Perdelli F, Cristina ML. Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings. J Prev Med Hyg. 2014 Dec;55(4):137-44. Review. PubMed PMID: 26137787.

6: Martínková J. [Current view of vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections]. Klin Mikrobiol Infekc Lek. 2015 Mar;21(1):16-23. Review. Czech. PubMed PMID: 26098489.

7: Chunhui C, Xiaogang X. Genetic characteristics of vancomycin resistance gene cluster in Enterococcus spp. Yi Chuan. 2015 May;37(5):452-7. doi: 10.16288/j.yczz.14-420. Review. PubMed PMID: 25998433.

8: Tsoulas C, Nathwani D. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer? Int J Antimicrob Agents. 2015 Jul;46(1):1-7. doi: 10.1016/j.ijantimicag.2015.03.011. Epub 2015 Apr 30. Review. PubMed PMID: 25982913.

9: Bruniera FR, Ferreira FM, Saviolli LR, Bacci MR, Feder D, da Luz Gonçalves Pedreira M, Sorgini Peterlini MA, Azzalis LA, Campos Junqueira VB, Fonseca FL. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):694-700. Review. PubMed PMID: 25753888.

10: Reardon J, Lau TT, Ensom MH. Vancomycin loading doses: a systematic review. Ann Pharmacother. 2015 May;49(5):557-65. doi: 10.1177/1060028015571163. Epub 2015 Feb 23. Review. PubMed PMID: 25712445.

11: Barber KE, King ST, Stover KR, Pogue JM. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev Anti Infect Ther. 2015 Mar;13(3):363-77. doi: 10.1586/14787210.2015.1001839. Review. PubMed PMID: 25661903.

12: Holmes NE, Tong SY, Davis JS, Hal SJ. Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med. 2015 Feb;36(1):17-30. doi: 10.1055/s-0034-1397040. Epub 2015 Feb 2. Review. PubMed PMID: 25643268.

13: Kang DG, Holekamp TF, Wagner SC, Lehman RA Jr. Intrasite vancomycin powder for the prevention of surgical site infection in spine surgery: a systematic literature review. Spine J. 2015 Apr 1;15(4):762-70. doi: 10.1016/j.spinee.2015.01.030. Epub 2015 Jan 28. Review. PubMed PMID: 25637469.

14: Mutters NT, Werner G, Tacconelli E, Mischnik A. [Treatment options for serious infections caused by vancomycin-resistant enterococci]. Dtsch Med Wochenschr. 2015 Jan;140(1):42-5. doi: 10.1055/s-0040-100428. Epub 2015 Jan 12. Review. German. PubMed PMID: 25580973.

15: Bakhsheshian J, Dahdaleh NS, Lam SK, Savage JW, Smith ZA. The use of vancomycin powder in modern spine surgery: systematic review and meta-analysis of the clinical evidence. World Neurosurg. 2015 May;83(5):816-23. doi: 10.1016/j.wneu.2014.12.033. Epub 2014 Dec 19. Review. PubMed PMID: 25535069.

16: Chuang YC, Wang JT, Lin HY, Chang SC. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis. 2014 Dec 13;14:687. doi: 10.1186/s12879-014-0687-9. Review. PubMed PMID: 25495779; PubMed Central PMCID: PMC4269951.

17: Rubinstein E, Keynan Y. Vancomycin revisited - 60 years later. Front Public Health. 2014 Oct 31;2:217. doi: 10.3389/fpubh.2014.00217. eCollection 2014. Review. PubMed PMID: 25401098; PubMed Central PMCID: PMC4215627.

18: Kacířová I, Grundmann M. [Therapeutic monitoring of vancomycin in routine clinical practice]. Vnitr Lek. 2014 Oct;60(10):846-51. Review. Czech. PubMed PMID: 25382007.

19: Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Dong W, Xing J, Dong Y. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015 Jan;71(1):107-15. doi: 10.1007/s00228-014-1775-x. Epub 2014 Oct 30. Review. PubMed PMID: 25355172.

20: Patel R, Gallagher JC. Vancomycin-resistant enterococcal bacteremia pharmacotherapy. Ann Pharmacother. 2015 Jan;49(1):69-85. doi: 10.1177/1060028014556879. Epub 2014 Oct 28. Review. PubMed PMID: 25352037.

Your view history

Vancomycin HCl featured